Shares of Inovio climbed in trading after the company announced its DNA vaccine candidate for Covid-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.
If you are not happy with the results below please do another search
50 search results for:
The United States is preparing for the possibility that a booster shot will be needed between nine to 12 months after people are initially vaccinated against Covid-19, a White House official said on April 15.
Germany’s Boehringer Ingelheim partnered with Denmark’s Zealand Pharma A/S to study the GLP-1/glucagon dual agonist BI 456906 in two Phase II trials as a potential treatment for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH).
GlaxoSmithKline halted two mid-stage studies assessing feladilimab combined with Merck’s Keytruda as a potential treatment in different oncology settings.
Merck is discontinuing development of MK-7710 (formerly known as CD24Fc), a Phase III Covid-19 therapeutic asset acquired from OncoImmune during November 2020.
The global supply of Covid-19 vaccine is “incredibly tight” and the COVAX dose-sharing facility is unlikely to procure much more supply in 2021 than doses already reserved, the Gavi vaccine alliance ceo Seth Berkley said on April 15.
The U.S. Centers for Disease Control and Prevention (CDC) said up to 5,800 people who have been fully vaccinated against coronavirus disease 2019 have been infected by the novel coronavirus following vaccination.
There is a much higher risk of brain blood clots from Covid-19 infection than there is from vaccines against the disease, British researchers said on April 15, after the rollout of inoculations was disrupted by reports of rare clots.
None of the 43 antibiotics in development as well as recently approved medicines are enough to combat the increasing emergence and spread of antimicrobial resistance, the World Health Organization cautioned on April 15.
Thermo Fisher Scientific Inc. is acquiring contract researcher PPD Inc. for $17.4 billion as the medical device maker adds more muscle to the company’s pharmaceutical services business.